UBS AM
BCYC

UBS AM’s Bicycle Therapeutics BCYC Stock Holding History

UBS AM’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,300
Closed -$190K – 2313
2025
Q2 		$190K Buy
27,300
+22,200
+435% +$177K ﹤0.01% 2567
2025
Q1 		$43.3K Buy
+5,100
New +$60.1K ﹤0.01% 2617

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

UBS AM's BCYC Position: Q3 2025 in Review

UBS AM sold out of Bicycle Therapeutics (BCYC) in Q3 2025, closing a stake of 27,300 shares — an estimated $190K sold.

UBS AM first reported a position in BCYC in Q1 2025 and held it in 2 quarters. The position peaked at $190K in Q2 2025. 99 funds tracked by Wall St. Rank hold BCYC as of Q3 2025.

  • UBS AM reported no remaining Bicycle Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 27,300 Bicycle Therapeutics shares in Q3 2025, an estimated $190K.
  • UBS AM first reported a position in Bicycle Therapeutics in Q1 2025 and held it in 2 quarters.
  • UBS AM's Bicycle Therapeutics position peaked at $190K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.